Opinions Jim Cramer - Mad Money
Emergent BioSolutions EBSCOMMENTMar 03, 2021
EBS is helping to produce Covid vaccines. Despite this, the stock has been hammered 25% from recent high, a victim of the current rotation favouring reopening stocks and dumping other sectors. The stock has gotten too cheap at 10x earnings; it's a growth stock.
Jim Cramer - Mad MoneyUnknown
$94.73
Stock price when the opinion was issued
$8.49
As of Jun 01, 2026. Market Open.
biotechnologypharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
You might be interested:
SELL
A disaster. He feels bad for J&J that they ever signed a contract with them.
biotechnologypharmaceutical
BUY
Instead of buying a single vaccine-making pharma, consider this. They have an established vaccine business and are working on plasma-based treatments for Covid. They also have a big contract manufacturing business of vaccines with JNJ, AZN and Novavax. This has fallen $40 from its August peak. But last night they issued bullish future numbers for this year, and the stock jumped 4.7% today. More upside to come.
biotechnologypharmaceutical
